A carregar...
Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies
Cariprazine, a potent dopamine D(3) and D(2) receptor partial agonist antipsychotic with preferential binding to D(3) receptors, is Food and Drug Administration approved for treating schizophrenia and manic or mixed episodes of bipolar I disorder. A post-hoc safety/tolerability analysis of data from...
Na minha lista:
| Publicado no: | Int Clin Psychopharmacol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Lippincott Williams And Wilkins
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5625952/ https://ncbi.nlm.nih.gov/pubmed/28692485 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/YIC.0000000000000187 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|